COVID-19 VACCINE: NOVAVAX DELAYS ITS LAST STAGE TRIALS TO NOVEMBER

Highlights

• Data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021 and could be the basis for regulatory approval said Novavax

• The pharma company said data from an early-to-mid stage or phase 2 trial of their experimental vaccine candidate is now expected on Friday

• On the other hand, other U.S. pharmaceutical companies like Pfizer Inc and AstraZe....